Physician profile
Margaret Brown
NPI 1730809955
$804.31
in general payments reported to CMS, 2019-2025
13 companies · $718 in 2025
The $718 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $86.05 · 2025: $718.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $804.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $804.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $193.40 | 2025 | Nucala, Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $117.41 | 2025 | Winrevair |
| Gilead Sciences, INC. | $92.49 | 2025 | Livdelzi |
| Teva Pharmaceuticals USA, INC. | $86.05 | 2024 | Austedo Xr |
| Electromed, INC. | $72.45 | 2025 | Smartvest |
| Chiesi USA, INC. | $47.65 | 2025 | Curosurf |
| Genzyme Corporation | $38.71 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $38.50 | 2025 | Dupixent |
| Baxter Healthcare | $32.10 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Actelion Pharmaceuticals US, INC. | $28.03 | 2025 | Opsynvi, Uptravi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.93 | 2025 | Jascayd |
| Philips North America LLC | $17.77 | 2025 | Vest Therapy Und |
| Astrazeneca Pharmaceuticals LP | $15.82 | 2025 | Airsupra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Margaret Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.